Frederik Denorme1, Tine Wyseure1, Miet Peeters1, Nele Vandeputte1, Ann Gils1, Hans Deckmyn1, Karen Vanhoorelbeke1, Paul J Declerck1, Simon F De Meyer2. 1. From the Laboratory for Thrombosis Research, KU Leuven Campus Kulak Kortrijk, Belgium (F.D., N.V., H.D., K.V., S.F.D.M.); and Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium (T.W., M.P., A.G., P.J.D.). 2. From the Laboratory for Thrombosis Research, KU Leuven Campus Kulak Kortrijk, Belgium (F.D., N.V., H.D., K.V., S.F.D.M.); and Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium (T.W., M.P., A.G., P.J.D.). simon.demeyer@kuleuven.be.
Abstract
BACKGROUND AND PURPOSE: Cerebral ischemia and reperfusion is associated with activation of the coagulation cascade and fibrin deposition in cerebral microvessels. Both thrombin-activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 (PAI-1) attenuate fibrinolysis and are therefore attractive targets for the treatment of ischemic stroke. METHODS: TAFI and PAI-1 were inhibited by monoclonal antibodies in a mouse model of transient middle cerebral artery occlusion. Twenty-four hours after stroke, mice were neurologically scored, cerebral thrombotic burden was assessed, and brain infarct sizes were calculated. RESULTS: Inhibition of TAFI or PAI-1 significantly decreased cerebral infarct sizes by 50% 24 hours after stroke. This reduction in cerebral damage was associated with a significant decrease in fibrin(ogen) deposition in the ischemic brain. Concurrently, functional recovery of the animals was improved. Interestingly, combined targeting of TAFI and PAI-1 using low, and by themselves inactive, doses of antibodies improved cerebral blood flow and reduced cerebral fibrin(ogen) deposition and infarct sizes by 50%. When dual treatment was delayed to 1 hour after the start of reperfusion, it still reduced brain injury; however, this was not statistically significant. CONCLUSIONS: Targeting of PAI-1 and TAFI is protective in an ischemic stroke model by attenuating fibrin(ogen) deposition, thereby improving reperfusion. Combined inhibition has a co-operative effect that could become useful in ischemic stroke therapy.
BACKGROUND AND PURPOSE:Cerebral ischemia and reperfusion is associated with activation of the coagulation cascade and fibrin deposition in cerebral microvessels. Both thrombin-activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 (PAI-1) attenuate fibrinolysis and are therefore attractive targets for the treatment of ischemic stroke. METHODS:TAFI and PAI-1 were inhibited by monoclonal antibodies in a mouse model of transient middle cerebral artery occlusion. Twenty-four hours after stroke, mice were neurologically scored, cerebral thrombotic burden was assessed, and brain infarct sizes were calculated. RESULTS: Inhibition of TAFI or PAI-1 significantly decreased cerebral infarct sizes by 50% 24 hours after stroke. This reduction in cerebral damage was associated with a significant decrease in fibrin(ogen) deposition in the ischemic brain. Concurrently, functional recovery of the animals was improved. Interestingly, combined targeting of TAFI and PAI-1 using low, and by themselves inactive, doses of antibodies improved cerebral blood flow and reduced cerebral fibrin(ogen) deposition and infarct sizes by 50%. When dual treatment was delayed to 1 hour after the start of reperfusion, it still reduced brain injury; however, this was not statistically significant. CONCLUSIONS: Targeting of PAI-1 and TAFI is protective in an ischemic stroke model by attenuating fibrin(ogen) deposition, thereby improving reperfusion. Combined inhibition has a co-operative effect that could become useful in ischemic stroke therapy.
Authors: Jean-Philippe Desilles; Lucas Di Meglio; Francois Delvoye; Benjamin Maïer; Michel Piotin; Benoît Ho-Tin-Noé; Mikael Mazighi Journal: Front Neurol Date: 2022-07-06 Impact factor: 4.086
Authors: Daniel Torrente; Enming Joseph Su; Linda Fredriksson; Mark Warnock; David Bushart; Kris M Mann; Cory D Emal; Daniel A Lawrence Journal: Transl Stroke Res Date: 2022-02-04 Impact factor: 6.800
Authors: Chunyang Wang; Rui Huang; Chao Li; Mei Lu; Martin Emanuele; Zheng Gang Zhang; Michael Chopp; Li Zhang Journal: Stroke Date: 2019-10-07 Impact factor: 7.914
Authors: Frederik Denorme; Bhanu Kanth Manne; Irina Portier; Alicia S Eustes; Yasuhiro Kosaka; Benjamin T Kile; Matthew T Rondina; Robert A Campbell Journal: Blood Date: 2020-02-06 Impact factor: 25.476